X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
MET642, a potent, sustained, non-bile acid farnesoid x-receptor (FXR) agonist, is a non-immunosuppressive treatment for inflammatory bowel disease, including ulcerative colitis and Crohn’s disease.
Lead Product(s): MET642
Therapeutic Area: Gastroenterology Product Name: MET642
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Equillium
Deal Size: $59.0 million Upfront Cash: Undisclosed
Deal Type: Termination December 23, 2022
Details:
Through the acquisition, Equillium adds Metacrine’s farnesoid X receptor platform, including lead molecule MET642, an orally delivered FXR agonist that is a non-immunosuppressive treatment for inflammatory bowel disease, including ulcerative colitis and Crohn’s disease.
Lead Product(s): MET642
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: MET642
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Equillium
Deal Size: $59.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition September 06, 2022
Details:
The Company’s two product candidates, MET409 and MET642, are currently being investigated in clinical trials as potential new treatments for NASH.
Lead Product(s): MET409
Therapeutic Area: Gastroenterology Product Name: MET409
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 06, 2021
Details:
MET642, an FXR Agonist with a Unique Chemotype is currently being investigated in clinical trials as potential new treatments for non-alcoholic steatohepatitis.
Lead Product(s): MET642
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: MET642
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 17, 2021
Details:
The Phase 2a study is a 16-week, randomized, placebo-controlled, multi-center trial evaluating the safety, tolerability and pharmacological activity of MET642 (3 mg and 6 mg). Full trial results of up to 180 patients are expected to be reported in the first half of 2022.
Lead Product(s): MET642
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: MET642
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2021
Details:
First patient has been treated in its Phase 2a trial of MET642, a potent, sustained, non-bile acid farnesoid x-receptor (FXR) agonist, for the treatment of patients with non-alcoholic steatohepatitis (NASH).
Lead Product(s): MET642
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: MET642
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2021
Details:
The findings showed robust and sustained FXR activation, which Metacrine believes is key to optimizing therapeutic benefits. Combined with a favorable pharmacological and tolerability profile, the results support the therapeutic potential of MET409 for patients with NASH.
Lead Product(s): MET409
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: MET409
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 01, 2020
Details:
MET409 demonstrated notable improvements in decreased liver fat content and differentiated impacts on pruritus and LDL cholesterol after 12 weeks of treatment in NASH patients .
Lead Product(s): MET409
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: MET409
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 27, 2020
Details:
U.S. Food & Drug Administration (FDA) has granted Fast Track designation to MET409, the company’s lead farnesoid X receptor (FXR) agonist, for the treatment of non-alcoholic steatohepatitis (NASH).
Lead Product(s): MET409
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: MET409
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2020
Details:
Randomized, placebo-controlled 12-week study showed mean liver fat reduction of up to 55% with MET409
Lead Product(s): MET409
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
